LL-37 (cathelicidin): what it is, and why the FDA is reviewing it next

The short version

• LL-37 is a germ-fighting peptide your own body makes. You find it in your skin, airways, gut lining and white blood cells. It is the only one of its family (the cathelicidins) that humans make.
• It attacks bacteria by breaking open their outer coat. In lab studies, that makes it harder for germs to become resistant to it than to ordinary antibiotics.
• It can calm inflammation, and it can also fuel it. It plays a part in skin conditions such as rosacea and psoriasis, and at higher concentrations it starts to damage the body's own cells.
• Human data are thin. Only a few small, mostly skin-applied wound studies exist, with local skin reactions and no serious whole-body side effects reported. Any benefit in people is unestablished because the large trials have not been run.
• Nominated, not approved. LL-37 is on the list for the FDA advisory committee's next review, expected before the end of February 2027. It is not FDA-approved and not on the 503A Bulks List (the list of ingredients pharmacies may compound from).
• Thymosin alpha-1 often comes up in the same conversations, but it works differently. It acts on T cells (immune cells that coordinate the immune response) rather than on germs. We explain the difference below.

Educational content, not medical advice. No doses, routes, protocols or sourcing information appears anywhere. LL-37 is not FDA-approved for any indication and is not on the 503A Bulks List. Being nominated for review is not an approval, a recommendation, or an indication of availability.

---

Most compounds in this space arrive via a supplement label or a forum. LL-37 is arriving via a regulatory calendar, which is a slightly unusual route and worth using well - because it means there is a dated, checkable fact at the centre of the story, and a lot of marketing about to be built on top of it.

What LL-37 is

Humans make exactly one cathelicidin. The gene is CAMP; it produces a precursor protein called hCAP18, and when that precursor is cleaved, the active fragment released is a 37-amino-acid peptide beginning with two leucines - LL-37.

It is part of the innate immune system: the fast, non-specific first layer of defence, as distinct from the adaptive immunity that produces antibodies. LL-37 is expressed at barrier surfaces - skin, airway lining, gut epithelium - and by neutrophils and other immune cells. Production increases in response to injury and infection.

Its best-characterised activity is antimicrobial. LL-37 is broadly active against Gram-positive and Gram-negative bacteria, and shows activity against bacterial biofilms. Mechanistically it is a cationic, amphipathic peptide: it carries a positive charge that draws it to negatively charged bacterial membranes, then disrupts them. Because it attacks membrane integrity rather than a specific enzyme, resistance is harder to develop against it than against conventional antibiotics - which is the central reason antimicrobial peptides attract research interest.

One clarification, because the terminology invites a claim. "Antimicrobial peptide" is a category label describing a class of molecules, not a statement that a given compound treats infections in people. Penicillin is an antimicrobial and so is bleach; the word tells you about mechanism, not about clinical use.

What the innate-immunity literature establishes

The laboratory and animal literature on LL-37 is substantial and genuinely interesting. It supports several things:

• Direct antimicrobial and anti-biofilm activity against a broad range of human pathogens in vitro.
• Wound-healing effects in animal and cell-culture models - LL-37 appears to promote re-epithelialisation and angiogenesis.
• Immunomodulation: LL-37 interacts with scavenger receptors and other receptors on immune cells, influencing their behaviour beyond simply killing microbes. In sepsis models, intravenous LL-37 improved survival in mice and inhibited caspase-1 activation and pyroptosis in peritoneal macrophages.
• Endogenous roles in human disease biology: LL-37 expression is altered in a range of conditions, and the CAMP gene is vitamin-D-responsive, which is one of the more solid mechanistic threads connecting vitamin D status to innate immune function.

That is a real body of work. It is also overwhelmingly preclinical - cell culture, animal models, and mechanistic studies - which places it at the same evidence tier we assign elsewhere in this library to compounds with interesting biology and thin human data.

The dual-role problem: the honest complication

This is the part that gets left out, and it is the most important thing on this page.

LL-37 is implicated in both host defence and inflammatory pathology. It is not simply a beneficial molecule that some people have too little of.

On the protective side: antimicrobial activity, wound healing, and the anti-inflammatory effects described above.

On the pathological side: LL-37 can drive inflammation. It binds nucleic acids - DNA and RNA released from damaged cells - and presents those complexes to immune receptors in a way that triggers inflammatory signalling that would not otherwise occur. Sequence features of LL-37 that promote inflammation via RNA presentation to scavenger receptors have been specifically characterised. Elevated LL-37 has been implicated in the pathology of inflammatory skin conditions, and it appears in the mechanistic literature on rosacea and psoriasis - in the role of contributor, not treatment. Its role in autoimmune conditions is an active research question for the same reason: a molecule that presents self-nucleic-acids to immune receptors is a plausible participant in autoimmunity.

The behaviour is also concentration-dependent. At lower concentrations LL-37 shows the modulatory and protective effects; at higher concentrations it becomes cytotoxic to host cells, promotes apoptosis, and amplifies acute inflammatory responses. A molecule whose effect reverses sign with concentration is a hard therapeutic problem, and it is a very hard unsupervised one.

So the honest summary is: LL-37 is not a compound with a simple direction of effect. Any framing that presents it as "your body's own anti-inflammatory" is describing half of it.

What human clinical evidence exists

Considerably less than the preclinical literature would lead you to expect.

Human trial experience is limited to a small number of studies, primarily using topical formulations in wound-related applications. Reported safety findings in those trials were local skin reactions at the application site, without serious systemic adverse events at the doses studied. That is a reassuring signal at the scale it was measured, and it is a small scale.

What does not exist, to our knowledge, is a body of large randomised trials establishing efficacy for any indication, or meaningful long-term human safety data for systemic administration. The gap between "extensively studied molecule" and "compound with established clinical use in people" is wide here, and the first phrase is doing a lot of work in marketing copy that the second cannot support.

Regulatory status: nominated, docketed, not approved

The dated facts, kept separate from each other:

The other four substances reported for that docket are GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF - covered in the second PCAC docket. The sitting is expected before the end of February 2027, and the FDA has published no date for it - nor any stated reason for splitting the peptide review across two meetings. Together the two sittings cover twelve of the nineteen peptides placed in Category 2 in 2023, which makes this a phased, compound-by-compound review rather than a blanket reversal: each substance is assessed on its own against the 503A criteria.

The sequence matters and is routinely compressed. A PCAC vote is a recommendation and is not binding on the FDA. After it, the FDA must review the docket, publish a proposed rule, run a public comment period, and issue a final rule - and the Secretary of Health and Human Services must formally approve the addition - before a substance sits on the 503A Bulks List. The mechanism is set out in what 503A compounding actually means. The July 2026 session demonstrates how slow this is in practice: six peptides were recommended that month and emideltide (DSIP) was not, and as of 20 October 2026 nothing has been added to the 503A Bulks List - no proposed rule has been published, none of the six is on the final list, and an interim enforcement-discretion policy sent to the White House Office of Management and Budget on 14 October 2026 has not yet been issued. LL-37 is two full steps behind those six, having not yet been voted on at all.

So the following are all false, and all of them will be published somewhere in the next six months: that LL-37 has been approved; that it is about to become available; that the FDA has endorsed it; that being on a docket reflects a safety assessment. Appearing on a review docket means a committee is scheduled to look at the evidence. That is the entire content of the fact.

What to watch for at the next PCAC

If you are tracking this properly, the useful signals are:

• Whether the FDA posts a firm date and a public comment docket. As of September 2026 neither had appeared, and "before the end of February 2027" is a reported expectation rather than a calendar entry.
• What proposed use LL-37 is nominated for. PCAC reviews a substance against a specific proposed indication, not in the abstract, and the indication shapes the whole discussion.
• How FDA's own scientific reviewers assess it. Staff review precedes the vote. In July 2026 the committee recommended six substances over its reviewers' objections, which tells you those two things can diverge.
• How the dual-role problem is handled. For a molecule implicated in inflammatory pathology as well as host defence, that is the substantive scientific question, and its treatment in the review will be more informative than the vote count.

Thymosin alpha-1: the thymus peptide people often mention alongside LL-37

If you read about LL-37, you will often see thymosin alpha-1 mentioned in the same breath. Both get called "immune peptides". They do very different jobs.

Where it comes from. The thymus is a small organ behind your breastbone. It is where T cells (white blood cells that coordinate and direct the immune response) mature and learn their job. The thymus is most active in childhood and shrinks with age. Thymosin alpha-1 is a short peptide first isolated from thymus tissue in the 1970s. The lab-made version is called thymalfasin.

What it is thought to do. In lab and animal studies, thymosin alpha-1 appears to support T-cell maturation. It also seems to help dendritic cells (the immune system's scouts, which show pieces of germs to T cells) send the right signals. In plain terms, it is studied as a way to tune how the immune system coordinates itself. It is not a germ-killer.

Where it is approved, and where it is not. Thymalfasin is sold as Zadaxin and is approved in a number of countries outside the US, mainly in Asia and Latin America. Its main approved use there is chronic hepatitis B, and in some places as an add-on to support the immune system. It is not FDA-approved, and in the US it is investigational.

What the bigger trials show. The results are mixed. Earlier, smaller studies in sepsis (a life-threatening overreaction of the body to an infection) hinted at a benefit. The largest trial so far, the TESTS trial from China, followed about 1,100 adults with sepsis and was published in the BMJ in 2025. It found almost no difference in deaths at 28 days compared with people on a dummy treatment (roughly 23% versus 24%). The researchers saw a possible benefit in people with diabetes, but that was a subgroup finding and needs its own trial before anyone relies on it.

How it differs from LL-37

A caution if you have an autoimmune condition. In an autoimmune disease, such as lupus, rheumatoid arthritis or Hashimoto's thyroiditis, the immune system already attacks your own body. Anything meant to turn immune activity up is a question mark in that setting, and that includes thymosin alpha-1. We explain why in peptides and autoimmune disease: why caution comes first. Talk it through with your own doctor first.

Where Vivre Labs fits. Unlike LL-37, thymosin alpha-1 is something Vivre Labs offers. It is available on its own as thymosin alpha-1, or as part of the calm inflammation and gut protocol, which pairs it with KPV and VIP (vasoactive intestinal peptide). These are investigational compounds, and we recommend starting with baseline bloodwork so you have a reference point. For a fuller look at the evidence, read our thymosin alpha-1 guide.

Frequently asked questions

What is LL-37? The only cathelicidin antimicrobial peptide produced by humans - a 37-amino-acid fragment cleaved from the precursor protein hCAP18, expressed at barrier surfaces and by immune cells as part of innate immunity. It has direct antimicrobial activity and broader immune-modulating effects.

Is LL-37 FDA approved? No. It is not approved for any indication and is not on the 503A Bulks List. It has been nominated for review at a PCAC session expected before the end of February 2027. Nomination is not approval and does not indicate any change in legal availability.

Is LL-37 anti-inflammatory? Partly, and partly the opposite - which is why the question does not have a clean answer. It has documented anti-inflammatory and immunomodulatory effects, and it is also implicated in driving inflammatory pathology by presenting nucleic acids to immune receptors, with a mechanistic role described in conditions including rosacea and psoriasis. Its behaviour is concentration-dependent, shifting from modulatory to cytotoxic at higher concentrations.

Does more LL-37 mean better immunity? There is no evidence supporting that, and the dual-role biology argues against assuming it. Elevated LL-37 is associated with inflammatory skin pathology in the research literature. This is not a molecule where "more" has been shown to be better.

Is thymosin alpha-1 the same as LL-37? No. LL-37 is a germ-fighting peptide that acts directly on bacteria and on the fast, first-line part of the immune system. Thymosin alpha-1 comes from the thymus and is thought to work on T cells, the part of the immune system that coordinates a targeted response. Thymosin alpha-1 is approved for hepatitis B in some countries outside the US but is not FDA-approved; LL-37 is not approved anywhere.

When will LL-37 be available? There is no answer to that question, because no step has been taken that would lead to availability. Even in the most favourable case - a positive committee vote, FDA acceptance, and completed rulemaking - that sequence takes well over a year from a vote that has not yet happened.

---

Where Vivre stands

LL-37 is a good molecule to think with, precisely because it resists the usual framing. It is not an exotic research chemical: it is something your own body makes, characterised in a large scientific literature, with real therapeutic interest behind it. It is also a molecule whose effects reverse direction with concentration and which appears in the mechanistic accounts of inflammatory disease - and it has been tested in humans only in a handful of small, mostly topical studies.

Our position is that the docket date is the least interesting fact here and the one most likely to be sold to you. The interesting fact is the dual role, and it is a reason for caution rather than enthusiasm. We are not offering this compound, and we would not, on the current evidence, regardless of how the committee votes.

If the immune and inflammatory side of your health is what brought you to this page, the useful step is measurement and a clinical conversation - not a compound that is two regulatory steps away from a process that itself creates no access.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore GHK-Cu or explore thymosin alpha-1.

Related reading

• The second PCAC docket · KPV · What 503A compounding actually means · Peptide legal status in 2026
• Thymosin alpha-1: what the evidence shows · The calm inflammation and gut protocol
• Peptides and autoimmune disease: why caution comes first - the LL-37 self-nucleic-acid mechanism and what it means if you have an autoimmune condition
• Part of Inflammation & Gut

---

Educational content, not medical advice. LL-37 is not FDA-approved for any indication and is not on the 503A Bulks List; nomination for committee review is not approval, recommendation, or an indication of availability. No doses, routes, protocols or sourcing information appears here. Claims for the Malaysian market are subject to MAB requirements. Regulatory dates are as reported and should be re-verified against FDA primary notices.

References

• LL-37 as the sole human cathelicidin; antimicrobial and anti-biofilm activity against Gram-positive and Gram-negative pathogens; wound-healing effects. Frontiers in Immunology (2013), The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00143/full
• Immunomodulatory effects via scavenger receptors: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821026/
• Pro-inflammatory sequence determinants - presentation of RNA to scavenger receptors: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214221/
• LL-37 inhibits macrophage pyroptosis and improves survival in polybacterial septic mice (animal model): https://pmc.ncbi.nlm.nih.gov/articles/PMC4888352/
• LL-37 in sepsis pathogenesis, treatment and diagnosis (review, 2025): https://pubmed.ncbi.nlm.nih.gov/40960088/
• Human trial experience: a small number of studies, primarily topical, reporting local application-site skin reactions without serious systemic adverse events at the doses studied.
• Next PCAC docket - five substances reported (GHK-Cu, Melanotan II, cathelicidin/LL-37, dihexa acetate, PEG-MGF), committee expected to reconvene before end of February 2027: Buchanan Ingersoll & Rooney, https://www.bipc.com/fda-pcac-recommends-six-peptides-for-the-503a-bulks-list-what-compounding-pharmacies-need-to-know
• PCAC votes are recommendations and are not binding on the FDA; notice-and-comment rulemaking is required and the Secretary of Health and Human Services must formally approve any addition. As of 20 October 2026 nothing has been added to the 503A Bulks List. An interim enforcement-discretion policy was submitted to the White House Office of Management and Budget on 14 October 2026 and has not been issued.
• July 2026 status as of 15 September 2026 (since updated: interim policy submitted to OMB 14 October 2026, not issued) - no proposed rule published, six recommended peptides not on the final 503A Bulks List: https://www.restorativecompounding.com/blog/fda-peptide-compounding-pcac-category-2-503a-bulks-list
• Background on FDA peptide regulation: Johns Hopkins Bloomberg School of Public Health, https://publichealth.jhu.edu/2026/how-the-fda-regulates-peptides
• Thymosin alpha-1 first isolated from thymus tissue: Goldstein AL, Low TL, McAdoo M, et al. "Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide." PNAS, 1977.
• Thymosin alpha-1 sepsis trial: Wu J, et al. (TESTS study collaborator group). "The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial." BMJ, 2025;388:e082583. 1,106 adults; 28-day all-cause mortality 23.4% vs 24.1%, hazard ratio 0.99 (95% CI 0.77 to 1.27). https://www.2minutemedicine.com/thymosin-%ce%b11-administration-not-associated-with-improved-mortality-in-septic-patients/
• Thymalfasin (Zadaxin) approved outside the US, mainly for chronic hepatitis B and as an immune adjunct; not FDA-approved. Country list to be verified against the manufacturer's current labelling before publication.
• ⚠️ For MAB review: named human trials (topical LL-37) to be cited individually with author and year before publication; PCAC date to be re-verified against the FDA primary notice when posted.